history of glp-1 agonists glucagon-like peptide-1 receptor Market Overview: GLP-1 Agonists and
Description
Incretin mimetics considerably expanded their proven benefits beyond obesity in 2024
A population-based study from Scandinavia provides some real-world information.
Learn about the Zepbound blindness lawsuit, including NAION and other eye side effects, and read about a study linking GLP-1 RAs to severe vision problems.
FDA thresholds, insurance cutoffs, qualifying conditions, and more.
How many people take GLP-1 medications
Aims/hypothesis Tirzepatide is a novel dual glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1 receptor agonist (GLP-1 RA) currently under review for marketing approval
